News
Market Access/ News/ News/ News/ R&D
AstraZeneca, Avillion ‘first-in-class’ combination inhaler shines in Phase 3 trial
Eloise McLennan
albuterol, asthma, Astra Zeneca, Avillion, budesonide
0 Comment
Lilly’s new drug Mounjaro (tirzepatide ) wins US FDA approval
Joy Persaud
Diabetes, Lilly, Mounjaro, Type 2 diabetes
0 Comment
FDA rejects UCB’s psoriasis therapy bimekizumab
Phil Taylor
bimekizumab, fda, psoriasis, regulatory, UCB
0 Comment
Market Access/ News/ News/ News/ Patients
Gedeon Richter gets NICE nod for uterine fibroids drug Ryeqo
Phil Taylor
Gedeon Richter, HEOR, NHS, NICE, patients, relugolix, uterine fibroids, women's health
0 Comment
Exit Aduhelm, enter lecanemab. Biogen and Eisai have another go
Phil Taylor
Aduhelm, Alzheimer's disease, amyloid, Biogen, Eisai, lecanemab, regulatory
0 Comment
Takeda spinout Phathom claims its first FDA approvals
Phil Taylor
gastroenterology, Helicobacter pylori, Phathom Pharmaceuticals, regulatory approval, Takeda, vonoprazan, Voquezna
0 Comment
Market Access/ News/ News/ News/ Patients
FDA approves first in vitro test for early Alzheimer’s disease
Phil Taylor
Alzheimer's disease, diagnosis, in vitro, neurology, regulatory approval
0 Comment
Market Access/ News/ News/ News/ Oncology
AZ eyes Q3 FDA decision for Imfinzi in biliary tract cancer
Phil Taylor
AstraZeneca, biliary tract cancer, Imfinzi, immuno-oncology, Oncology
0 Comment